What Tirzepatide Is
Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid peptide studied as a dual agonist of two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It is engineered with a C20 fatty-acid moiety that binds serum albumin, extending its half-life to roughly five days and supporting once-weekly dosing schedules in the published clinical literature. This guide reviews its receptor pharmacology and reported research context for Canadian laboratories — as a scientific reference only, not as guidance for human use.
For the receptor-by-receptor comparison against its neighbours, see Retatrutide vs Tirzepatide vs Semaglutide, and for the single-molecule background, the tirzepatide encyclopedia entry.
The Dual-Agonist Mechanism
Where semaglutide is a single GLP-1 receptor agonist, tirzepatide's defining feature in the research literature is that it engages two receptors at once:
- GLP-1 receptor. The same incretin pathway targeted by semaglutide, associated in the literature with insulin secretion and satiety signalling.
- GIP receptor. A second incretin receptor. The published rationale for adding GIP agonism is that the two incretin signals are studied as complementary, with reported additive effects on metabolic endpoints in trial data.
This places tirzepatide one step "up" from the single-agonist semaglutide and one step "below" the triple agonist retatrutide, which adds a third (glucagon) receptor. The three form a clear progression that the three-way comparison guide lays out in full.
Structure and Pharmacology at a Glance
| Property | Tirzepatide |
|---|---|
| Development code | LY3298176 |
| Class | Dual GLP-1 / GIP receptor agonist |
| Length | 39 amino acids |
| Half-life | ~5 days |
| Albumin binding | C20 fatty-acid moiety |
| Comparison neighbours | semaglutide (single agonist), retatrutide (triple agonist) |
The ~5-day half-life and albumin-binding design are the structural features most relevant to how the compound behaves in solution and across a study timeline.
Reported Clinical-Trial Literature (Research Context Only)
Tirzepatide has an extensive published trial record under its manufacturer's development program. That literature reports endpoints around glycemic and metabolic measures in human trials. For a Canadian research buyer, the relevance of this literature is strictly as scientific context for why the compound is studied — it is not a statement that the compound is approved for, or should be used in, any human or veterinary application by the reader. Tirzepatide sold as a research peptide is for in vitro and preclinical laboratory work only.
Handling: Reconstitution and Storage
Tirzepatide ships lyophilized and must be reconstituted before laboratory use:
- Use quality bacteriostatic water as the diluent — solution integrity depends on diluent quality as much as peptide purity, as the bacteriostatic water guide explains.
- Follow the peptide reconstitution guide for concentration calculations and correct technique; use the Tirzepatide reconstitution calculator for the concentration math.
- Store per the peptide storage guide — lyophilized powder and reconstituted solution have distinct stability windows, and GLP-1-class peptides are sensitive to freeze-thaw cycling.
Verifying Purity Before You Rely on It
As with any GLP-1-class research peptide, the batch Certificate of Analysis is what turns a labelled purity number into a measured one. Independent third-party HPLC and mass-spec results — not an in-house figure — are the standard to insist on; see /lab-reports for published batch documentation and the Canadian vendor-selection guide for the full due-diligence framework.
Buying Tirzepatide for Research in Canada
Lux BioPure stocks Tirzepatide 10mg for domestic Canadian research fulfillment, alongside semaglutide and retatrutide in the same metabolic-research class. Browse the full shop for current in-stock inventory, and read the Canadian buyer's guide for sourcing context.
Frequently Asked Questions
What receptors does tirzepatide target? Tirzepatide is a dual agonist of the GLP-1 receptor and the GIP receptor — two incretin receptors. Engaging both is its defining feature versus semaglutide, which targets GLP-1 alone. Retatrutide adds a third receptor (glucagon), making it a triple agonist.
How is tirzepatide different from semaglutide? Semaglutide is a single GLP-1 receptor agonist; tirzepatide adds a second incretin target, the GIP receptor, making it a dual agonist. The two are compared receptor-by-receptor, alongside the triple agonist retatrutide, in the three-way research comparison guide.
What is tirzepatide's half-life? Tirzepatide has a half-life of roughly five days, supported by a C20 fatty-acid moiety that binds serum albumin. That structural feature is what underlies the once-weekly dosing schedules used in the published clinical-trial literature.
Is tirzepatide sold as a research peptide the same as an approved medicine? No. Tirzepatide sold as a research peptide is supplied for in vitro and preclinical laboratory research use only and is not an approved medicine for the buyer. Its published human clinical-trial literature is scientific context only, not an indication for human or veterinary use.
Research Disclaimer
This guide reviews the published receptor pharmacology and research literature of tirzepatide for in vitro and preclinical laboratory contexts only. Tirzepatide is not approved for human or veterinary therapeutic use by the reader under Health Canada or any regulatory authority, and nothing in this article constitutes medical advice, dosing guidance, or a recommendation for administration to humans or animals.